

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

HOS

RRID:CVCL_0312

Type: Cell Line

Proper Citation

RRID:CVCL_0312

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0312

Proper Citation: RRID:CVCL_0312

Description: Cell line HOS is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Osteosarcoma

Defining Citation: [PMID:1385192](#), [PMID:2233717](#), [PMID:2463881](#), [PMID:2823272](#), [PMID:6954533](#), [PMID:12645653](#), [PMID:15150091](#), [PMID:15289353](#), [PMID:17981215](#), [PMID:19787792](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21519327](#), [PMID:22460905](#), [PMID:23144859](#), [PMID:26320182](#), [PMID:26351324](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HOS

Cross References: BTO:BTO_0003904, CLO:CLO_0003795, CLO:CLO_0050810, EFO:EFO_0002196, MCCL:MCC:0000205, CLDB:cl1702, CLDB:cl1706, CLDB:cl17155, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1543, BCRC:60308, BCRJ:0339, BioSample:SAMN01821560, BioSample:SAMN01821729, BioSample:SAMN03471393, BioSample:SAMN10987602, cancercellines:CVCL_0312, CCRID:1101HUM-

PUMC000038, CCRID:4201HUM-CCTCC00333, CCRID:5301HUM-KCB15015YJ, CCTCC:GDC0251, CCTCC:GDC0333, Cell_Model_Passport:SIDM00806, ChEMBL-Cells:ChEMBL3308811, ChEMBL-Targets:ChEMBL614173, ChEMBL-Targets:ChEMBL614736, CLS:300449, CLS:300468, Cosmic:687928, Cosmic:759899, Cosmic:907060, Cosmic:931037, Cosmic:931910, Cosmic:1044082, Cosmic:1070840, Cosmic:1074391, Cosmic:1176621, Cosmic:1529902, Cosmic:2816208, Cosmic-CLP:907060, DepMap:ACH-000613, ECACC:87070202, EGA:EGAS00001000978, GDSC:907060, GEO:GSM170248, GEO:GSM185087, GEO:GSM185088, GEO:GSM320827, GEO:GSM827319, GEO:GSM879208, GEO:GSM887088, GEO:GSM888159, GEO:GSM1669891, GEO:GSM1676300, GEO:GSM1701635, GEO:GSM1914984, GEO:GSM1914985, GEO:GSM1914986, GEO:GSM1914987, GEO:GSM1915023, GEO:GSM1915024, GEO:GSM2635315, GEO:GSM2635316, GEO:GSM5087472, GEO:GSM5087473, GEO:GSM5087474, GEO:GSM5087475, GEO:GSM5087476, GEO:GSM5087477, IARC_TP53:27020, ICLC:HTL04003, IGRhCellID:HOS, IZSLER:BS TCL 69, JCRB:IFO50106, KCB:KCB 2015015YJ, LiGeA:CCLE_703, LINCS_LDP:LCL-1421, PharmacDB:HOS_563_2019, PRIDE:PXD022868, PRIDE:PXD030304, Progenetix:CVCL_0312, PubChem_Cell_line:CVCL_0312, RCB:RCB0992, Wikidata:Q54890160

ID: CVCL_0312

Record Creation Time: 20220427T220439+0000

Record Last Update: 20260829T233912+0000

Ratings and Alerts

No rating or validation information has been found for HOS.

No alerts have been found for HOS.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tao Y, et al. (2026) TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. Cancer research, 86(9), 2161.

Xu G, et al. (2026) Machine Learning-Based Identification and Validation of PYCR1 and PYGM as Prognostic Biomarkers for Osteosarcoma. Clinical Medicine Insights. Oncology, 20, 11795549261452567.

Wang J, et al. (2026) Prognostic characteristics of disulfidptosis-related genes across cancers and their potential implications in osteosarcoma. Science progress, 109(2),

368504261464856.

Wang S, et al. (2026) ANXA3 activates HIF-1 α /VEGF Signaling Via the PI3K/AKT/mTOR Pathway to Promote Osteosarcoma Stem Cell-Like Phenotype. *Stem cell reviews and reports*, 22(6), 2919.

Peng M, et al. (2026) In vitro modeling of nutritional and mitochondria-targeted therapies for osteosarcoma. *bioRxiv : the preprint server for biology*.

Bai G, et al. (2026) LARS promotes osteosarcoma proliferation through leucine-dependent PRIM2 translation and DNA replication activation. *Journal of experimental & clinical cancer research : CR*, 45(1).

Wang Y, et al. (2026) Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models. *Molecular cancer therapeutics*, 25(6), 881.

Gillman AN, et al. (2026) Comprehensive mapping of the virus and host factors that guide the paths of HIV-1 escape from a therapeutic. *Cell reports*, 45(7), 117558.

Lee SJ, et al. (2026) Hypoxia restores the acidosis-induced inhibition of cancer cell dissemination. *Cell reports*, 45(2), 116970.

Horak I, et al. (2026) Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2-COL3A1 axis. *Molecular oncology*.

Zhao T, et al. (2025) Derepressing nuclear pyruvate dehydrogenase induces therapeutic cancer cell reprogramming. *Cell metabolism*, 37(8), 1667.

Dai C, et al. (2025) Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression. *Journal of translational medicine*, 23(1), 900.

Mu H, et al. (2025) Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. *Cell reports. Medicine*, 6(3), 101977.

Liu F, et al. (2025) Integrated analysis of single-cell and bulk transcriptomics reveals cellular subtypes and molecular features associated with osteosarcoma prognosis. *BMC cancer*, 25(1), 280.

Zhang Y, et al. (2024) Circ_0002669 promotes osteosarcoma tumorigenesis through directly binding to MYCBP and sponging miR-889-3p. *Biology direct*, 19(1), 25.

Fu X, et al. (2024) Repurposing AS1411 for constructing ANM-PROTACs. *Cell chemical biology*, 31(7), 1290.

Hu X, et al. (2024) MTF2 facilitates the advancement of osteosarcoma through mediating EZH2/SFRP1/Wnt signaling. *Journal of orthopaedic surgery and research*, 19(1), 467.

Li X, et al. (2024) Identification of TNFRSF21 as an inhibitory factor of osteosarcoma based on a necroptosis-related prognostic gene signature and molecular experiments. *Cancer cell international*, 24(1), 14.

Pezzella M, et al. (2024) Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells. *Journal of hematology & oncology*, 17(1), 127.

Zhang Z, et al. (2024) Membrane HIV-1 envelope glycoproteins stabilized more strongly in a pretriggered conformation than natural virus Envs. *iScience*, 27(7), 110141.